Europe Ovarian Cancer Diagnostics Market
市场规模（十亿美元）
CAGR :
% 
USD
1,874.16 Billion
USD
3,093.84 Billion
2022
2030
 Forecast Period |
2023 –2030 |
 Market Size (Base Year) |
USD 1,874.16 Billion |
 Market Size (Forecast Year) |
USD 3,093.84 Billion |
 CAGR |
% |
| Major Markets Players |
欧洲卵巢癌诊断市场，按产品类型（仪器、试剂盒和试剂）、程序类型（活检测试、医学影像测试、血液标志物测试和基因测试）、癌症类型（生殖细胞、上皮肿瘤和基质细胞肿瘤）、最终用户（癌症诊断中心、医院实验室、研究机构等）划分 - 行业趋势和预测到 2030 年。
欧洲卵巢癌诊断市场分析与洞察
卵巢癌是卵巢组织中形成的癌症类型（卵巢是一对女性生殖腺之一，卵巢内形成卵子）。大多数卵巢癌是卵巢上皮癌（始于卵巢表面细胞的癌症）或恶性生殖细胞肿瘤（始于卵细胞的癌症）。用于诊断卵巢癌的检查和程序包括盆腔检查、影像学检查、血液检查、手术等。在盆腔检查期间，医生会将戴手套的手指插入阴道，同时用手按压腹部以触摸（触诊）盆腔器官。
欧洲卵巢癌诊断市场预计将在 2023 年至 2030 年的预测期内增长。Data Bridge Market Research 分析称，在 2023 年至 2030 年的预测期内，该市场将以 6.5% 的复合年增长率增长，预计到 2030 年将从 2022 年的 18.7416 亿美元达到 30.9384 亿美元。
|
报告指标 |
细节 |
|
预测期 |
2023 至 2030 年 |
|
基准年 |
2022 |
|
历史岁月 |
2021 (可定制至 2020-2016) |
|
定量单位 |
收入（百万美元） |
|
涵盖的领域 |
按产品类型（仪器、试剂盒和试剂）、程序类型（活检测试、医学影像测试、血液标志物测试和基因测试）、癌症类型（生殖细胞、上皮肿瘤和基质细胞肿瘤）、最终用户（癌症诊断中心、医院实验室、研究机构等） |
|
覆盖国家 |
德国、法国、英国、意大利、西班牙、荷兰、俄罗斯、瑞士、土耳其、比利时和欧洲其他地区 |
|
涵盖的市场参与者 |
F. Hoffmann-La Roche Ltd、Tosoh India Pvt. Ltd.、Luminex Corporation、Quest Diagnostics Incorporated、Thermo Fisher Scientific Inc.、Ngenebio、Abbott、Siemens healthcare private limited、Myriad Genetics Inc.、Bio-rad Laboratories, Inc.、R&d systems, Inc.、Foundation Medicine, Inc.、Biosupply ltd、Lcm genect srl、Inex innovate private limited、Abcam plc.、Monobind Inc.、Fujirebio、Mp biomedicals、Biovision Inc.、Boster biotechnology、Biogenix Inc. Pvt. Ltd.、Genway biotech 和 Lifespan biosciences, Inc. |
欧洲卵巢癌诊断市场的市场定义
卵巢癌最常见于 50 至 79 岁的女性。随着世界老年人口的增长以及对早期发现和治疗的重视，卵巢癌变得越来越普遍，这有望加速卵巢癌诊断市场的发展。政府加大对提高人们对早期癌症检测的认识的投资以及增加医疗保健支出也将推动业务增长。肥胖似乎在卵巢癌的发展中起着重要作用。其他可能增加风险的生活方式选择包括吸烟、饮酒和不生孩子。由于卵巢癌不易被发现，有患上这种疾病风险的女性必须接受常规检测以尽早发现这种疾病，从而使市场得以扩大。
由于市场参与者的增加和先进服务的可用性，欧洲卵巢癌诊断市场在预测年内将增长。与此同时，制造商正致力于研发活动，以在市场上推出新服务。卵巢癌诊断和开发方面的研究不断增加，进一步推动了市场的增长。然而，卵巢癌筛查技术的困难可能会阻碍预测期内欧洲卵巢癌诊断市场的增长。
欧洲卵巢癌诊断市场动态
驱动程序
- 卵巢癌认知度不断提高
人们对卵巢癌的认识不断提高，导致对及时检测癌症的需求增加，从而促进市场增长。
卵巢癌是全球女性死亡率上升的主要原因之一，这将推动未来五年的市场增长。由于环境因素和基因突变等各种因素，卵巢癌和囊肿变得越来越常见。
卵巢癌是一种影响女性卵子产生器官——卵巢的癌症。卵巢癌很难诊断，因为症状不明显，而且通常只有在癌症扩散到胃和骨盆后才被发现，因此很难治愈。
因此，需要改进诊断流程和技术来确定需要治疗的癌症阶段。此外，卵巢癌死亡率的上升令人担忧，这强调了早期发现以便提供治疗的重要性。
由于人们对卵巢癌认识的提高，预计它将成为市场增长的驱动因素。
- 改进的诊断流程和技术
筛查测试和检查用于检测没有任何症状的人群的疾病，例如癌症。已经进行了大量研究来开发卵巢癌的筛查测试，但迄今为止尚未取得太大成功。除全面盆腔检查外，最常用于筛查卵巢癌的两项测试是经阴道超声 (TVUS) 和 CA-125 血液测试。
阴道超声检查是一种将超声波探头插入阴道，利用声波检查子宫、输卵管和卵巢的检查。它可以帮助发现卵巢中的肿块（肿瘤），但无法真正判断肿块是癌症还是良性。当它用于筛查时，发现的大多数肿块都不是癌症。
CA-125 血液检测测量血液中一种名为 CA-125 的蛋白质的含量。许多卵巢癌女性的 CA-125 水平较高。该检测可作为肿瘤标志物，帮助指导已知患有卵巢癌的女性的治疗，因为如果治疗有效，CA-125 水平通常会下降。但检测 CA-125 水平不如卵巢癌筛查检测有用。
因此，由于诊断过程和技术的改进，预计它将成为市场增长的驱动因素。
限制
诊断费用高昂
全球范围内，癌症治疗费用不断上涨。医疗行业面临着癌症治疗医疗费用等诸多挑战。2010 年癌症治疗费用为 1246 亿美元，预计到 2020 年将增至 1730 亿美元，主要驱动因素是癌症药物价格和急性住院治疗。因此，诊断剂生产成本的增加阻碍了市场的增长。
缺乏熟练的专业人员
参与诊断过程的医疗保健专业人员有义务和道德责任运用临床推理技能，评估和管理患者的医疗问题。当诊断准确且及时时，患者最有可能获得积极的健康结果，因为临床决策将根据对患者健康问题的正确理解进行量身定制。缺乏熟练的专业人员可能会阻碍患者的康复过程，从而可能阻碍市场增长。
机会
癌症诊断和治疗的医疗支出增加
在全球范围内，由于公共卫生支出和经济表现，研发活动不断增加，而医疗保健行业在医疗保健支出方面位居所有行业第二位。医疗保健支出的增加可以带来更好的研发机会。预计这将增加对卵巢癌诊断的需求。
癌症治疗医疗支出的增加也有助于患者轻松接受先进的诊断和治疗，从而快速康复。医疗支出由自付费用（患者自费治疗）、政府支出以及医疗保险和非政府组织（NGO）活动等来源组成。由于癌症治疗医疗支出的增加，这为市场增长提供了机会。
挑战
癌症诊断产品审批及商业化的严格法规和标准
任何产品在市场上的商业化都受到严格的监管，这对美国和欧洲地区的癌症诊断产品制造商来说都是一个巨大的挑战。每个国家都有自己的法规，并且监管程序的机构也不同。
不同产品的营销批准、符合性声明和监管审查所需的时间可能有所不同。未能获得监管部门批准的公司会损害业务，因为没有获得产品批准，制造商就无法将其产品推向市场，因此，对癌症诊断产品的批准和商业化的严格规定和标准成为市场增长的制约因素。
最新动态
- 2022 年 11 月，Myriad Genetics Inc. 宣布收购 Gateway Genomics, LLC。此次收购增强了 Myriad Genetics 的女性健康产品组合，扩大了女性在生殖阶段及以后获得个性化基因检测的机会。借助 SneakPeek，Myriad 现在为怀孕早期的女性提供服务，通过 Prequel 无创产前筛查、Foresight 携带者筛查和 MyRisk 遗传性癌症测试（带风险评分）为所有血统的女性提供终生数据驱动的基因洞察，这将有助于公司增加收入。
- 2022年10月，Quest Diagnostics宣布与Decode health开启新一轮合作，在合作的初始阶段，双方基于各自的新一代测序、分析和临床专业知识开发了RNA（转录组）测序能力。此次合作意义重大，因为基于生物标志物的数据有助于减少开发新型诊断测试和确定不同类型癌症（乳腺癌、前列腺癌和卵巢癌）新药物靶点的时间和成本。此次合作有助于该公司在研发领域找到创新路径，并扩大该公司在欧洲的影响力。
欧洲卵巢癌诊断市场范围
欧洲卵巢癌诊断市场分为产品类型、程序类型、癌症类型和最终用户。这些细分市场之间的增长将帮助您分析行业中增长微弱的细分市场，并为用户提供有价值的市场概览和市场洞察，以便做出战略决策，确定核心市场应用。
产品类型
- 仪器
- 试剂盒和试剂
根据产品类型，欧洲卵巢癌诊断市场分为仪器、试剂盒和试剂。
程序类型
- 血液标志物检测
- 医学影像检查
- 活检检查
- 基因检测
根据程序类型，欧洲卵巢癌诊断市场细分为血液标志物检测、医学影像检测、活检检测和基因检测
癌症类型
- 上皮性肿瘤
- 生殖细胞
- 基质细胞瘤
根据癌症类型，欧洲卵巢癌诊断市场细分为上皮肿瘤、生殖细胞肿瘤和基质细胞肿瘤
最终用户
- 癌症诊断中心
- 医院实验室
- 研究机构
- 其他的
根据最终用户，欧洲卵巢癌诊断市场细分为癌症诊断中心、医院实验室、研究机构和其他
欧洲卵巢癌诊断市场区域分析/见解
对欧洲卵巢癌诊断市场进行了分析，并按国家、产品类型、程序类型、癌症类型和最终用户提供了市场规模洞察和趋势，如上所述。
本市场报告涵盖的国家包括德国、法国、英国、意大利、西班牙、荷兰、俄罗斯、瑞士、土耳其、比利时和欧洲其他地区。
德国在市场份额和收入方面占据欧洲卵巢癌诊断市场的主导地位，并将在预测期内继续保持主导地位。这是由于该地区神经系统疾病的患病率和发病率很高，而不断增长的研发投资和新产品的推出正在推动市场的发展
报告的国家部分还提供了影响单个市场因素和市场法规变化的信息，这些因素和变化会影响市场的当前和未来趋势。新旧销售、国家人口统计、疾病流行病学和进出口关税等数据点是预测单个国家市场情况的一些主要指标。此外，在对国家数据进行预测分析时，还考虑了欧洲品牌的存在和可用性以及它们因本土和国内品牌的竞争而面临的挑战以及销售渠道的影响。
竞争格局和欧洲卵巢癌诊断市场份额分析
卵巢癌诊断市场竞争格局提供了按竞争对手划分的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、欧洲业务、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对卵巢癌诊断市场的关注有关。
欧洲卵巢癌诊断市场的一些主要参与者包括 F. Hoffmann-la roche ltd、Tosoh india pvt. Ltd.、Luminex corporation、Quest diagnosticscorporated、Thermo fisher scientific Inc.、Ngenebio、Abbott、Siemens healthcare private limited、Myriad Genetics Inc.、Bio-rad laboratories, Inc.、R&d systems, Inc.、Foundation medicine, Inc.、Biosupply ltd、Lcm genect srl、Abcam plc.、Monobind Inc.、Fujirebio、Mp biomedicals、Biovision Inc.、Boster biotechnology、Genway biotech 和 Lifespan biosciences, Inc 等。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE OVARIAN CANCER DIAGNOSTICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET TESTING TYPE COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 GROWTH STRATEGIES ADOPTED BY KEY MARKET PLAYERS
5 INDUSTRY INSIGHTS
5.1 CONCLUSION
6 REGULATIONS OF THE EUROPE OVARIAN CANCER DIAGNOSTICS MARKET
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 GROWING OVARIAN CANCER AWARENESS
7.1.2 IMPROVED DIAGNOSTIC PROCESSES AND TECHNIQUES
7.1.3 INCREASE IN NUMBER OF NEW CASES EVERY YEAR
7.1.4 IMPROVED IMAGING TECHNIQUES
7.2 RESTRAINS
7.2.1 HIGH COST OF DIAGNOSIS
7.2.2 ADVERSE EFFECTS OF THE TREATMENT
7.3 OPPORTUNITIES
7.3.1 INCREASING HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT
7.3.2 GOVERNMENT INITIATIVES TOWARDS CANCER DIAGNOSTICS
7.4 CHALLENGES
7.4.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF CANCER DIAGNOSTIC PRODUCTS
7.4.2 LACK OF SKILLED PROFESSIONALS
8 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE
8.1 OVERVIEW
8.2 INSTRUMENTS
8.3 KITS AND REAGENTS
9 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE
9.1 OVERVIEW
9.2 BLOOD MARKERS TESTING
9.3 MEDICAL IMAGING TEST
9.4 BIOPSY TEST
9.5 GENETIC TESTING
10 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE
10.1 OVERVIEW
10.2 EPITHELIAL TUMOR
10.3 GERM CELL
10.4 STROMAL CELL TUMOR
11 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER
11.1 OVERVIEW
11.2 CANCER DIAGNOSTIC CENTERS
11.3 HOSPITAL LABORATORIES
11.4 RESEARCH INSTITUTES
11.5 OTHERS
12 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY GEOGRAPHY
12.1 EUROPE
12.1.1 GERMANY
12.1.2 FRANCE
12.1.3 U.K.
12.1.4 ITALY
12.1.5 SPAIN
12.1.6 RUSSIA
12.1.7 TURKEY
12.1.8 BELGIUM
12.1.9 NETHERLANDS
12.1.10 SWITZERLAND
12.1.11 REST OF EUROPE
13 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: EUROPE
14 SWOT ANALYSIS
15 COMPANY PROFILE
15.1 F. HOFFMANN-LA ROCHE LTD
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENTS
15.2 TOSOH INDIA PVT. LTD.
15.2.1 COMPANY SNAPSHOT
15.2.2 COMPANY SHARE ANALYSIS
15.2.3 PRODUCT PORTFOLIO
15.2.4 RECENT DEVELOPMENT
15.3 LUMINEX CORPORATION (2022)
15.3.1 COMPANY SNAPSHOT
15.3.2 COMPANY SHARE ANALYSIS
15.3.3 PRODUCT PORTFOLIO
15.3.4 RECENT DEVELOPMENT
15.4 QUEST DIAGNOSTICS INCORPORATED (2022)
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 COMPANY SHARE ANALYSIS
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPMENTS
15.5 THERMO FISHER SCIENTIFIC INC
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 COMPANY SHARE ANALYSIS
15.5.4 PRODUCT PORTFOLIO
15.5.5 RECENT DEVELOPMENT
15.6 ABBOTT
15.6.1 COMPANY SNAPSHOT
15.6.2 REVENUE ANALYSIS
15.6.3 PRODUCT PORTFOLIO
15.6.4 RECENT DEVELOPMENT
15.7 ABCAM PLC (2022)
15.7.1 COMPANY SNAPSHOT
15.7.2 REVENUE ANALYSIS
15.7.3 PRODUCT PORTFOLIO
15.7.4 1.7.4 RECENT DEVELOPMENT
15.8 BIOSUPPLY LTD
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENT
15.9 BIO-RADBIO LABORATORIES
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENTS
15.1 BIOVISION INC.
15.10.1 COMPANY SNAPSHOT
15.10.2 PRODUCT PORTFOLIO
15.10.3 RECENT DEVELOPMENT
15.11 BIOGENIX INC. PVT. LTD.
15.11.1 COMPANY SNAPSHOT
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENT
15.12 BOSTER BIOLOGICAL TECHNOLOGY
15.12.1 COMPANY SNAPSHOT
15.12.2 PRODUCT PORTFOLIO
15.12.3 RECENT DEVELOPMENT
15.13 FOUNDATION MEDICINE
15.13.1 COMPANY SNAPSHOT
15.13.2 PRODUCT PORTFOLIO
15.13.3 RECENT DEVELOPMENT
15.14 FUJIREBIO
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENT
15.15 GENWAY BIOTECH
15.15.1 COMPANY SNAPSHOT
15.15.2 PRODUCT PORTFOLIO
15.15.3 RECENT DEVELOPMENT
15.16 INEX INNOVATIVE PRIVATE LIMITED
15.16.1 COMPANY SNAPSHOT
15.16.2 PRODUCT PORTFOLIO
15.16.3 RECENT DEVELOPMENT
15.17 LCM GENETIC SRL
15.17.1 COMPANY SNAPSHOT
15.17.2 PRODUCT PORTFOLIO
15.17.3 RECENT DEVELOPMENT
15.18 LIFESPAN BIOSCIENCES, INC
15.18.1 COMPANY SNAPSHOT
15.18.2 PRODUCT PORTFOLIO
15.18.3 RECENT DEVELOPMENTS
15.19 MP BIOMEDICALS
15.19.1 COMPANY SNAPSHOT
15.19.2 PRODUCT PORTFOLIO
15.19.3 RECENT DEVELOPMENT
15.2 MONOBIND INC.
15.20.1 COMPANY SNAPSHOT
15.20.2 PRODUCT PORTFOLIO
15.20.3 RECENT DEVELOPMENT
15.21 MYRIAD GENETICS, INC.
15.21.1 COMPANY SNAPSHOT
15.21.2 REVENUE ANALYSIS
15.21.3 PRODUCT PORTFOLIO
15.21.4 RECENT DEVELOPMENT
15.22 NGENEBIO
15.22.1 COMPANY SNAPSHOT
15.22.2 PRODUCT PORTFOLIO
15.22.3 RECENT DEVELOPMENTS
15.23 R&D SYSTEMS, INC.
15.23.1 COMPANY SNAPSHOT
15.23.2 PRODUCT PORTFOLIO
15.23.3 RECENT DEVELOPMENT
15.24 SIEMENS MEDICAL SOLUTIONS
15.24.1 COMPANY SNAPSHOT
15.24.2 REVENUE ANALYSIS
15.24.3 PRODUCT PORTFOLIO
15.24.4 RECENT DEVELOPMENT
16 QUESTIONNAIRE
17 RELATED REPORTS
表格列表
TABLE 1 24-MONTH EPISODE-OF-CARE COSTS FOR EARLY-STAGE AND LATE-STAGE CANCERS BY PAYER (USD BILLION)
TABLE 2 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 3 EUROPE INSTRUMENTS IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 4 EUROPE KITS AND REAGENTS IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 5 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 6 EUROPE BLOOD MARKERS TESTING IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 7 EUROPE MEDICAL IMAGING TEST IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 8 EUROPE BIOPSY TEST IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 9 EUROPE GENETIC TESTING IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 10 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 11 EUROPE EPITHELIAL TUMOR IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 EUROPE GERM CELL IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 13 EUROPE STROMAL CELL TUMOR IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 15 EUROPE CANCER DIAGNOSTIC CENTERS IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 EUROPE HOSPITAL LABORATORIES IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 EUROPE RESEARCH INSTITUTES IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 EUROPE OTHERS IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 20 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 21 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 22 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 23 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 24 GERMANY OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 25 GERMANY OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 26 GERMANY OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 27 GERMANY OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 28 FRANCE OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 29 FRANCE OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 30 FRANCE OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 31 FRANCE OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 32 U.K. OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 33 U.K. OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 34 U.K. OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 35 U.K. OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 36 ITALY OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 37 ITALY OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 38 ITALY OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 39 ITALY OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 40 SPAIN OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 41 SPAIN OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 42 SPAIN OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 43 SPAIN OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 44 RUSSIA OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 45 RUSSIA OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 46 RUSSIA OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 47 RUSSIA OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 48 TURKEY OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 49 TURKEY OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 50 TURKEY OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 51 TURKEY OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 52 BELGIUM OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 53 BELGIUM OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 54 BELGIUM OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 55 BELGIUM OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 56 NETHERLANDS OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 57 NETHERLANDS OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 58 NETHERLANDS OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 59 NETHERLANDS OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 60 SWITZERLAND OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 61 SWITZERLAND OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 62 SWITZERLAND OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 63 SWITZERLAND OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 64 REST OF EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 65 REST OF EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)
TABLE 66 REST OF EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 67 REST OF EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
图片列表
FIGURE 1 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET : SEGMENTATION
FIGURE 2 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET : DATA TRIANGULATION
FIGURE 3 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET : DROC ANALYSIS
FIGURE 4 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET : EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET : COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET : INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET : DBMR MARKET POSITION GRID
FIGURE 8 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET : MARKET TESTING TYPE COVERAGE GRID
FIGURE 9 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET : VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET : SEGMENTATION
FIGURE 11 THE INCREASE IN THE AWARENESS ABOUT OVARIAN CANCER IS EXPECTED TO DRIVE THE EUROPE OVARIAN CANCER DIAGNOSTICS MARKET IN THE FORECAST PERIOD OF 2022 TO 2030
FIGURE 12 PRODUCT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE OVARIAN CANCER DIAGNOSTICS MARKET IN 2022 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGE OF THE EUROPE OVARIAN CANCER DIAGNOSTICS MARKET
FIGURE 14 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022
FIGURE 15 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)
FIGURE 16 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 17 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 18 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: BY PROCEDURE TYPE, 2022
FIGURE 19 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: BY PROCEDURE TYPE, 2023-2030 (USD MILLION)
FIGURE 20 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: BY PROCEDURE TYPE, CAGR (2023-2030)
FIGURE 21 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: BY PROCEDURE TYPE, LIFELINE CURVE
FIGURE 22 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2022
FIGURE 23 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION)
FIGURE 24 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030)
FIGURE 25 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE
FIGURE 26 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: BY END USER, 2022
FIGURE 27 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 28 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 29 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE
FIGURE 30 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 31 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 32 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 33 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 34 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE (2023-2030)
FIGURE 35 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
